B O O K - American College of Rheumatology

More documents

Recommendations

Info

abstract KEYWORD INDEX health education 1006, 1318, 1336, 1337, 1338, 1465, 2062, 2077, 2082, 2249 health information technology 998 health related quality of life 1872 health services research 72 health services use 2055 health status 184, 1462 health status outcomes 1461 healthcare 969 health-related quality of life (HRQoL) 1407, 1837 healthy controls 2245 healthy volunteers 1273 heart disease 459, 626, 1059 heart failure 1059 heart rate variability 808 heath utility 1558 heat-shock proteins 681, 1093, 1729 heavy metal 2153 helplessness 2140 help-seeking 2282 hematopoietic stem cells 351, 426 hemochromatosis 818, 886 hemophagocytic lymphohistiocytosis 653 hemophagocytic syndrome 26 hemorrhagic cystitis 2026 hepatic disorders 1178, 1762 hepatic magnetic elastography 129 hepatitis 387, 892, 1639, 1646, 2030, 2039, 2046 hepatitis C 1646, 2024, 2131 hepatotoxicity 75 hepcidin 1309 heritability 877 heterogeneity 52 HFE gene 886 HIDS 1698 HIF 1418 high density lipoprotein 1189 high mobility group box 1 1195 high throughput sequencing 1604 highly active anti-retroviral therapies (HAART) 966 high-resolution computed tomography 119 hip 963, 2137 hip disorders 529, 972, 2094 hip fracture 972 hip structure analysis 960 hippocampus 1159 Hispanic patients 305, 1465, 1768, 2148 histochemistry 927 histone 507, 750 histone deacethylase inhibitor (Trishostatin A) 1715 histone deacetylase 1484, 2191 histopathology 1151 histoplasmosis 1643 HLA 725 HLA class II associations 66 HLA-B27 552, 1448, 1969, 1973 HLA-DRB1 shared epitope 2118 HMGB1 1297 home health 1005 homebound 2110 hormones 747, 1040 hospitalized patients 163 hr-pqct 136 human 1270 human anti-chimeric antibodies (HACA’s) 1826 human follicular helper T cell 1246 human immunodeficiency virus (HIV) 966, 1645 human leukocyte antigens (HLA) 66, 256, 549, 645, 832, 1092, 1216, 1313, 1355, 1450, 1605, 1966, 1973, 1974, 1975, 1979, 2114 human papillomavirus (HPV) 464, 996 humanized SLE mouse 427 hyaluronate 1711 hydroxychloroquine 463, 484, 732, 1860, 1865, 2150, 2238, 2239, 2241, 2255 hygiene hypothesis 248 hyper IgD 1685 hyper-IgD syndrome 2105 hyperimmunoglobulinemia D with periodic fever syndrome 1698 hypermobility 1342 hypertension 878, 888, 1367, 1565, 1569, 2155 hyperuricemia 160, 161, 874, 876, 878, 879, 883, 884, 992, 1363, 1367, 1547, 1614, 1861, 2088, 2154, 2155 hypodermis 1624 hypothalamic-pituitary-adrenal axis 649 hypoxia 360, 630, 1418, 1510 ibandronate 964 ibuprofen 945, 946 ICOS 1141 idiopathic pulmonary artery hypertension 598 IFNa 494 IFN-gamma 428 IgA antiphospholipid assays 14 IgG4-related systemic disease 1671 IKKβ 1107 IL-1 265, 897, 1622 IL-1 receptor antagobist 260 IL-1 suppression 891 IL-1 trap 1831 I IL-1ß 2150 IL-10 274, 1732 IL13 833 IL-13 polymorphism 1984 IL-15 1801 IL-17 276, 323, 365, 428, 896, 1041, 1730, 1838, 1970, 1992, 2130, 2232 IL-17 F 1515 IL-17 induced arthritis 270 IL-17 receptor 1976 IL-17A 1274, 1515 IL-18 903, 923, 1664 IL-18 binding protein 1664 IL-18BP 282 IL-2 therapy 2131 IL-21 432, 1088, 1594 IL-22 275, 715, 1992 IL-23 1260, 1970 IL-23R 1078 IL-27 276, 714 IL-32 371 IL-33 28 IL-5 2203 IL-6 18, 1109, 1293, 1800, 1996 IL-6R 1996 IL-7 receptor 1900, 1903 IL-9 1241 ILD 402 imaging 1022 imaging techniques 118, 119, 120, 136, 138, 540, 650, 889, 964, 1051, 1370, 1617, 1622, 1624, 1625, 1628, 1634, 1728, 1822, 1887, 1931, 1983, 2097 imatinib 560, 566, 573, 1189, 1990, 1997, 2020, 2193 imiglucerase 1653 immune 1313 immune complexes 263, 499, 1020, 1399, 1601 immune reconstitution 1161 immune response 752, 1037, 1440, 1580, 1581, 2216 immune response to vaccination 792 immune complex 504, 866 immunizations 457 immunogenicity 464 immunoglobulin (IG) 465, 504, 828, 1085, 1604 immunoglobulin free light chains 333 immunohistochemistry 482, 927 immunological profile 1908 immunology 1430 immunoregulation 442 immunosuppression 1157, 2043 immunosuppressive drugs 1865 immunotherapy 1116, 1714 364 2010 Program Book
impact 1063, 1325 inactive disease 2220 INCB028050 2172 inception cohort 2273 incidence 112, 568 incidence rate 972 inclusion body myositis 922 index 1878 indigenous peoples 1538 indomethacin 151 indoor falls 684 inducible NO synthase (iNOS) 1489 inefficacy 1110 infection 237, 248, 313, 316, 335, 341, 342, 346, 400, 403, 414, 421, 698, 758, 782, 1381, 1390, 1638, 1640, 1642, 1643, 1648, 1649, 1669, 1678, 1876, 1969, 2023, 2103, 2216 inflammasome 265, 2228 inflammation 86, 88, 106, 134, 145, 151, 260, 270, 288, 360, 369, 441, 443, 499, 536, 675, 679, 714, 844, 854, 855, 864, 866, 949, 1034, 1041, 1081, 1109, 1130, 1239, 1270, 1296, 1309, 1422, 1424, 1426, 1470, 1506, 1509, 1512, 1524, 1525, 1533, 1607, 1622, 1707, 1728, 1761, 1785, 1813, 1883, 1953, 2044, 2078, 2109, 2150, 2162, 2200, 2204, 2229, 2231, 2233, 2260 inflammatory arthritis 19, 28, 300, 629, 659, 712, 716, 766, 778, 794, 890, 901, 904, 978, 997, 1029, 1067, 1391, 1418, 1427, 1665, 1710, 1729, 1737, 2227 inflammatory back pain 544 inflammatory bowel disease (IBD) 223, 537, 901 inflammatory diseases 2217 inflammatory markers 385 infliximab 216, 234, 328, 352, 381, 420, 988, 1276, 1300, 1436, 1542, 1680, 1743, 1826, 1829, 1945, 1960, 2265 influenza 224, 237, 478, 1238 influenza vaccine 1694 information needs 1408 information technology 221, 2111, 2284 infusion therapy 1002 inhibitor 1358 inhibitory kappaB 1487 injection 947, 1567, 1626, 2225 innate immune cells 866 innate immunity 845, 935, 1883, 2230 innate lymphocyte 2232 in-patient 1576 insole 2134 instrument validation 1337 insulin receptor 1514 insulin resistance 389 insulin-like growth factor 670, 1501 integrins 844, 865, 1719 intensive care unit 2102 inter- and intra-observer agreement 1623 inter- and intra-rater variability 1623 inter-disciplinary consensus 1212 interferon regulatory factor 433, 1712 interferon signature 1904 interferon-γ assay 756 interferon-gamma release assay 782 interferon-regulatory factor-4 435 interferons 271, 428, 433, 493, 494, 496, 501, 503, 850, 868, 934, 1164, 1181, 1183, 1199, 1376, 1660, 1661, 1712, 1904, 2187, 2188, 2189, 2278 interfreon-alpha 1181 interleukin (IL) -32 277 interleukin 1 1831 interleukin 1 receptor antagonist 271 interleukin 6 1247 interleukin-1 272 interleukin-1 receptor associated kinase-1 1587 interleukin-13 675 interleukin-17 1271 interleukin-18 703 interleukin-1b (IL-1)- 1489 interleukin-23 1271 interleukin-6 30, 272, 1096, 2168 interleukin-7 278 interleukins (IL) 18, 19, 29, 35, 152, 153, 260, 265, 271, 276, 278, 282, 353, 358, 369, 371, 373, 432, 629, 637, 657, 707, 831, 895, 903, 1088, 1121, 1124, 1126, 1241, 1260, 1270, 1308, 1412, 1435, 1488, 1531, 1607, 1664, 1831, 1903, 1970, 2158, 2203 interlleukin-2 receptor alpha (sIL-2Ra) 49 intermittent and constant osteoarthritis pain (ICOAP) 682 international 969, 1013 internet 1340, 1362 internet survey 807 internet use 1409 interprofessional practice 2050 inter-rater discrimination 1652 interstitial keratitis 1675 interstitial lung disease 592, 602, 919, 932, 1035, 1044, 1086, 1377, 1672, 1803, 1824 interstitial pneumonia 1042 intestinal Behcet’s disease 1300 intestinal involvement 1297 intestinal microbiota 1390 intestinal parasitosis 539 intima media thickness 455 intimal hyperplasia 1294 intima-media thickness 1028 intra articular 943, 947, 2225 intracellular signalling 1357 intracranial hemorrhage 2037 intravenous immunoglobulin (IVIG) 494, 576 invasion 1387, 1421 ion channels 1270 iontophoresis 218 IRF-1 282 IRF5 1607 iridocyclitis 528 IR-induced DNA damage 509 ITGAM 637 J JAK1/JAK2 2172 janus kinase (JAK) 269, 717, 1137, 1240, 2171, 2172, 2233 janus kinase 2 (JAK2) inhibition 2233 janus-kinase-1 2200 Japanese 237, 399, 1285, 1577, 1672 JNK 32 job 2139 job loss 80, 781, 1541, 1548, 2079 joint count 166, 723, 1759 joint damage 2109 joint destruction 32, 73, 132, 272, 367, 536, 716, 887, 1470, 1479, 1482, 1495, 1600, 1610, 1738, 1747, 1785, 1812, 1821, 1828, 2256, 2258, 2273 joint distraction 176, 1380 joint examination 1781 joint procedures 1539 joint space distance 136 joint space narrowing 132, 707, 1369 joint swelling 79, 2258 junctional adhesion molecule 1419 juvenile arthritis 207, 220, 224, 251, 259, 1407, 2219 juvenile dermatomyositis 242, 252, 928, 1344, 1672, 1678, 1700 juvenile fibromyalgia 807 juvenile idiopathic arthritis (JIA) 206, 208, 209, 210, 213, 214, 216, 217, 218, 219, 222, 224, 226, 227, 228, 229, 230, 231, 232, 235, 236, 237, 238, 239, 243, 244, 245, 247, 248, 250, 253, 254, 255, 256, 258, 263, 264, 654, 655, 1012, 1339, 1404, 1405, 1406, 1408, 1434, 1491, 1601, 1630, 2084, 2103, 2219, 2220, 2248 juvenile idiopathic arthritis-enthesitis (ERA) 219, 233, 235, 266 juvenile localized scleroderma of the face 1687 juvenile myositis 1379, 1678 juvenile onset patients 1697 juvenile polyarteritis nodosa 2033 juvenile psoriatic arthritis 219 juvenile scleroderma 1439, 1682, 1687, 1704 juvenile sclerosis 1704 juvenile spondylarthropathy 212, 225, 266, 1633 abstract KEYWORD INDEX 2010 Program Book 365
Page 1 and 2:
program B O O K Pre-Conference Cour
Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
Page 11 and 12:
the written consent of the ACR is p
Page 13 and 14:
Shuttle Bus Service See shuttle sig
Page 15 and 16:
ACR Resource Center Hours: Sunday,
Page 17 and 18:
ACR Hotels + Map Complimentary shut
Page 19 and 20:
to the premier meeting in rheumatol
Page 21 and 22:
ACR Clinical Research Conference c/
Page 23 and 24:
4:20 PM Germinal Center Reactions A
Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
Page 27 and 28:
Upon completion of this session, pa
Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
Page 31 and 32:
B301 Dermatological Manifestations
Page 33 and 34:
Session Overview: The innate immune
Page 35 and 36:
Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
Page 39 and 40:
and insufficiency • recall source
Page 41 and 42:
Session Overview: The advent of bio
Page 43 and 44:
2:45 pm 641. Major Improvements in
Page 45 and 46:
5 University of Twente and Medisch
Page 47 and 48:
ACR/ARHP Combined Abstract Session
Page 49 and 50:
REF 25th Anniversary Celebration 2:
Page 51 and 52:
5:45 PM 699. Defining Latent and/or
Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
Page 59 and 60:
• discuss the principles of early
Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
Page 65 and 66:
ACR Plenary Session II: Discovery 2
Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
Page 69 and 70:
Session Overview: As a clinical edu
Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
Page 77 and 78:
2:45 PM 1405. Development of a Visi
Page 79 and 80:
4:30 PM Anti-citrullinated Protein
Page 81 and 82:
of Experimental Orthopedics, Univer
Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
Page 91 and 92:
• compare the prevalence and epid
Page 93 and 94:
6:45 PM Macrophage Activation Syndr
Page 95 and 96:
Page 97 and 98:
Session Overview: This roundtable d
Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
Page 103 and 104:
• describe the role of IL-1 and I
Page 105 and 106:
Session Overview: For the clinician
Page 107 and 108:
• identify the aspects for day-to
Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
Page 111 and 112:
Session Overview: Ultrasound and ma
Page 113 and 114:
Session Overview: Fifty percent of
Page 115 and 116:
1:20 PM Academic Rheumatology Seth
Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
Page 123 and 124:
Session Overview: We are witnessing
Page 125 and 126:
Session Overview: Systemic sclerosi
Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
Page 131 and 132:
4:30 PM 2198. Association between V
Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
Page 137 and 138:
• apply these basic statistics to
Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
Page 141 and 142:
Immunology, Oslo University Hospita
Page 143 and 144:
9:15 AM 2239. Factors Associated wi
Page 145 and 146:
Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
Page 151 and 152:
ACR Poster Session A Cytokines, Med
Page 153 and 154:
ACR Poster Session A 51. Associatio
Page 155 and 156:
ACR Poster Session A 83. Respirator
Page 157 and 158:
ACR Poster Session A 121. Bone Dens
Page 159 and 160:
ACR Poster Session A 142. The Intra
Page 161 and 162:
ACR Poster Session A 171. Early Pro
Page 163 and 164:
ACR Poster Session A Pediatric Rheu
Page 165 and 166:
ACR Poster Session A 233. Prevalenc
Page 167 and 168:
ACR Poster Session A 266. Subtype S
Page 169 and 170:
ACR Poster Session A 297. Body Weig
Page 171 and 172:
ACR Poster Session A 325. Patient R
Page 173 and 174:
ACR Poster Session A 356. Influence
Page 175 and 176:
ACR Poster Session A 383. Efficacy
Page 177 and 178:
ACR Poster Session A 409. Rituximab
Page 179 and 180:
ACR Poster Session A 441. Recombina
Page 181 and 182:
ACR Poster Session A 465. Immunoglo
Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
Page 187 and 188:
ACR Poster Session A 546. Prevalenc
Page 189 and 190:
ACR Poster Session A 571. Epidemiol
Page 191 and 192:
ACR Poster Session A 599. Validatio
Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
Page 195 and 196:
ACR Poster Session B 767. Economic
Page 197 and 198:
ACR/ARHP Poster Session B 792. The
Page 199 and 200:
ACR/ARHP Poster Session B Universit
Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
Page 207 and 208:
ACR/ARHP Poster Session B 935. The
Page 209 and 210:
ACR/ARHP Poster Session B 967. Frac
Page 211 and 212:
ACR Poster Session B 993. Early Exp
Page 213 and 214:
ACR/ARHP Poster Session B 1022. Com
Page 215 and 216:
ACR/ARHP Poster Session B 1055. Son
Page 217 and 218:
ACR Poster Session B 1084. Gene Exp
Page 219 and 220:
ACR/ARHP Poster Session B 1111. Inc
Page 221 and 222:
ACR Poster Session B hiroshima Memo
Page 223 and 224:
ACR/ARHP Poster Session B 1166. Pre
Page 225 and 226:
ACR/ARHP Poster Session B 1199. Typ
Page 227 and 228:
ACR/ARHP Poster Session B 1225. Phy
Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
Page 263 and 264:
ACR/ARHP Poster Session C Immunolog
Page 265 and 266:
ACR/ARHP Poster Session C 2 Departm
Page 267 and 268:
ACR/ARHP Poster Session C CA, 29 Un
Page 269 and 270:
ACR/ARHP Poster Session C 1900. IL-
Page 271 and 272:
ACR/ARHP Poster Session C 1930. Cor
Page 273 and 274:
ACR/ARHP Poster Session C 1958. The
Page 275 and 276:
ACR/ARHP Poster Session C 1988. Cha
Page 277 and 278:
ACR/ARHP Poster Session C 2015. CpG
Page 279 and 280:
ACR/ARHP Poster Session C 2038. Pri
Page 281 and 282:
ACR/ARHP Poster Session C 2070. Ass
Page 283 and 284:
REF Industry Roundtable-supported S
Page 285 and 286:
REF Industry Roundtable-supported S
Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
Page 305 and 306:
Cooper, Max D, MD Introduction . .
Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
Page 309 and 310:
Physical Examination Skills for Imp
Page 311 and 312:
Meroni, Pierluigi, MD Autoantibodie
Page 313 and 314:
Rogers, Joan C, PhD, OTR/ L Underst
Page 315 and 316: Terkeltaub, Robert, MD Crystallizin
Page 317 and 318: A Aarden, L 1825 Aarrass, S 1519, 1
Page 319 and 320: Bakker, AAB 1095 Barendregt, B 753
Page 321 and 322: Boutin-Le Thi Huong, D 478 Bout-Tab
Page 323 and 324: Chatham, WW 457, 1146, 1454, 1457,
Page 325 and 326: Daudon, M 875 Daugas, E 2009 Davatc
Page 327 and 328: Ehst, B 758 Eicher, JL 688 Eisen, S
Page 329 and 330: Gabay, OH 1484 Gaber, T 630, 1418 G
Page 331 and 332: Guan, M 965 Guañabens, N 975 Gudbj
Page 333 and 334: Homme, CL 730 Honda, E 434 Hong, JY
Page 335 and 336: Kambayashi, T 1354 Kamdar, AA 1160
Page 337 and 338: Kuller, LH 71 Kumabe, M 1164 Kumaga
Page 339 and 340: Looney, C 941 Looney, MR 609 Looney
Page 341 and 342: McCarthy, GM 1109, 1306, 1426 McCau
Page 343 and 344: Myouzen, K 1577 Mysiw, WJ 2096 Mysl
Page 345 and 346: Pans, M 1834 Parra, ER 605, 887 Ped
Page 347 and 348: Radka, S 1174 Radner, H 296, 1745 R
Page 349 and 350: Sack, KE 1898 Sacli, SF 1312 Saddic
Page 351 and 352: 1463, 2071, 2140, 2141 Singh, K 212
Page 353 and 354: Takahata, M 1492 Takasaki, Y 1731 T
Page 355 and 356: 636 van Dongen, CJJ 90 Van Doornum,
Page 357 and 358: Witte, T 824, 1578, 1579, 2214 Witt
Page 359 and 360: A α-galactosylceramide 505 A2A kno
Page 361 and 362: Behcet’s syndrome 1284, 1288, 129
Page 363 and 364: cost-utility 759, 1539 couples 1324
Page 365: fibroblast like synoviocyte 27 fibr
Page 369 and 370: methylation 826, 1253, 1489 methylt
Page 371 and 372: 233, 234, 240, 243, 252, 262, 268,
Page 373 and 374: 1599, 1600, 1603, 1605, 1606, 1609,
Page 375 and 376: 1226, 1227, 1229, 1230, 1231, 1233,
Page 377 and 378: Abelson, Abby Goulder, MD Education
Page 379 and 380: Massarotti, Elena M, MD Systemic Lu
Page 381 and 382: ACR Annual Meeting fellowS-in-train
Page 383 and 384: NOTES 2010 Program Book 381
Page 385 and 386: Enbrel ® (etanercept) Brief Summar
Page 387 and 388: Prescription Enbrel ® (etanercept)
show all

B O O K - American College of Rheumatology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?